ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid function tests have been originally described with sunitinib, we now know that many TKIs can induce hypothyroidism and hyperthyroidism. In this study, the various molecules implicated in thyroid dysfunctions are analysed and the latest data on physiopathological mechanisms are approached in order to propose a strategy of thyroid monitoring of patients on TKI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Bex, M., Carmeliet, P., & Schöffski, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604497 · Cited by 198
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Abdulrahman, R. M., Verloop, H., Hoftijzer, H., Verburg, E., Hovens, G. C., Corssmit, E. P., Reiners, C., Gelderblom, H., Pereira, A. M., Kapiteijn, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2507 · Cited by 112
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Maynard, M. A., Marino-Enriquez, A., Fletcher, J. A., Dorfman, D. M., Raut, C. P., Yassa, L., Guo, C., Wang, Y., Dorfman, C., Feldman, H. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308893 · Cited by 70
Cited by
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“, interferon-a) (20), or tyrosine kinase inhibitor therapy (21), and in the postpartum period it is referred to as postpartum thyroiditis (22).”
BackgroundDiverse origins of the myofibroblast—implications for kidney fibrosis
Falke, L. L., Gholizadeh, S., Goldschmeding, R., Kok, R. J., & Nguyen, T. Q. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.246 · Cited by 299
Groeneweg, S., van Geest, F. S., Peeters, R. P., Heuer, H., & Visser, W. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz008 · Cited by 216
Burch, H. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1901214 · Cited by 164
Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility
Soh, S.-B., & Aw, T.-C. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.1.3 · Cited by 136
Metadata
- Authors
- Illouz, F., Braun, D., Briet, C., Schweizer, U., & Rodien, P.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-09
- Volume
- 171
- Issue
- 3
- Pages
- R91-R99
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2170317569
- Cited by
- 95
- References
- 10
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors. https://app.cochat.ai/papers/10.1530/eje-14-0198
- The paper
- Illouz, F., Braun, D., Briet, C., Schweizer, U., & Rodien, P. (2014). ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors. European Journal of Endocrinology. https://doi.org/10.1530/eje-14-0198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.